Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BRICK1 pseudogene 1 (BRK1P1) is a processed pseudogene in the human genome. Pseudogenes arise from coding genes through mutation, duplication, or retrotransposition events, most often resulting in a locus unable to code for a functional protein. While some pseudogenes can regulate gene expression by competing for shared microRNAs or interacting with RNA-binding proteins, most have no known biological function. BRK1P1 is not known to encode a functional protein, is not a recognized therapeutic target, and currently has no established clinical or disease associations. The presence of "pseudogene" in the name and the "P" in the abbreviation indicate this is not an active protein-coding gene but an inactive or non-functional remnant. There is no evidence that BRICK1 pseudogene 1 has therapeutic relevance or interacts with drugs, nor is it established as a biomarker or safety concern. These features make it an incorrect choice as a canonical drug target. If you need information on a functionally relevant BRICK1 protein or canonical drug target, clarification is required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BRICK1 pseudogene 1 (BRK1P1).